Legal & General Group PLC Rain Therapeutics Inc. Transaction History

Legal & General Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.09 - $9.93 $2,079 - $18,946	1,908 New	1,908 $2,000
Q2 2022 Aug 22, 2022	SELL	$2.21 - $5.56 $3,505 - $8,818	-1,586 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.07 - $13.68 $517 - $1,395	102 Added 6.87%	1,586 $8,000
Q4 2021 Feb 14, 2022	BUY	$11.91 - $17.0 $9,170 - $13,090	770 Added 107.84%	1,484 $19,000
Q2 2021 Aug 12, 2021	BUY	$15.08 - $20.3 $10,767 - $14,494	714 New	714 $11,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.